Corporate Profile
We are a biotechnology company dedicated to developing next-generation therapeutics to improve the lives of patients with severe and life-altering brain diseases. Bright Minds’ broad portfolio of new chemical entities (NCEs) are positioned to treat a variety of pain indications, seizures, and neuropsychiatric disorders. By leveraging the extensive drug discovery experience of the Bright Minds team, we are creating a pipeline of best-in-class 5-HT (serotonin) medicines. Our patented, lead product candidates feature next generation characteristics, reducing unwanted side effects and maximizing therapeutic attributes. Bright Minds compounds are targeted therapies that allow for treatment of specific patient populations.
Issued and Outstanding shares
6,948,489*
*As of November 1, 2024
Research Coverage
| Firm | Analyst | Phone | |
|---|---|---|---|
| Eight Capital | Sepehr Manochehry, PhD | +1 416-849-7801 | smanochehry@viiicapital.com |
Stock information
Stock Chart
Press Releases
11/04/2024
10/21/2024
10/18/2024
10/03/2024
09/19/2024
09/12/2024
02/14/2024
02/14/2024
02/14/2024
12/06/2023
08/08/2023
07/20/2023
07/11/2023
06/22/2023
04/19/2023
04/10/2023
02/27/2023
02/17/2023
02/08/2023
01/27/2023
01/09/2023
12/2/2022
11/28/2022
11/22/2022
09/13/2022
08/31/2022
08/30/2022
08/23/2022
08/22/2022
08/18/2022
06/27/2022
05/12/2022
05/02/2022
04/19/2022
03/14/2022
03/09/2022
01/04/2022
12/06/2021
11/30/2021
11/03/2021
10/07/2021
09/22/2021
08/09/2021
08/18/2021
06/16/2021
06/14/2021
06/11/2021
06/09/2021
05/17/2021
05/11/2021
05/04/2021
04/23/2021
04/23/2021
03/17/2021
03/15/2021
03/10/2021
03/03/2021
02/23/2021
02/22/2021
02/10/2021
02/05/2021
Corporate Governance
Bright Minds Biosciences Inc. - Committee Composition Table
| Audit Committee | Nominating and Corporate Governance Committee |
Compensation Committee | Corporate Disclosure Committee | |
|---|---|---|---|---|
| Nils Bottler | Chair | Chair | Chair | Chair |
| Jeremy Fryzuk | Member | Member | Member | Member |
| David Weiner | Member | Member | Member | Member |
In the Media
11/24/2021
11/09/2021
08/26/2021
07/12/2021
07/07/2021
07/04/2021
06/30/2021
06/24/2021
02/02/2021
12/17/2020
12/16/2020
11/25/2020
08/07/2020
05/15/2020
08/12/2020
06/15/2020
Investor FAQs
Bright Minds was founded in 2017
September 30th
DRUG trading on the Canadian Securities Exchange (CSE)
DRUG trading on the Canadian Securities Exchange (CSE)
DRUG trading on the NASDAQ
You can submit queries to Bright Minds’ investor relations department by contacting
Partnering
If you are a pharmaceutical company interested in partnering with Bright Minds on one of our programs: partnering@brightmindsbio.com
Info
If you are a researcher interested in collaborating with Bright Minds or have a general question for the company: info@brightmindsbio.com
Press
Are you in publishing and looking for additional information? write us at: press@brightmindsbio.com
Jobs
Interested in joining our team and helping to shape the future of brain health: jobs@brightmindsbio.com
